---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277165"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:55:47.035961+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha Q3 net loss $117.1M on warrant expense; TSHA-102 well-tolerated with clinical improvements

## Summary
- Net loss $117.1M ($0.93/shr) includes $100.5M non-cash fair value change in warrant liability; prior year net loss $26.5M.
- Cash and cash equivalents $164.3M; runway extended into 2026 via new loan with Trinity Capital (no financial covenants or warrants).
- TSHA-102 first two adult patients: well-tolerated, no SAEs; sustained improvements in autonomic, motor, socialization functions at week 12 (patient 1) and week 4 (patient 2).
- IDMC cleared dosing of third adult patient; low-dose cohort completion and first U.S. pediatric dosing expected Q1 2024.
- R&D expenses $11.8M (down from $16.8M YoY) due to lower headcount and licensing fees, partially offset by clinical trial costs.

## SEC filing metadata
- accession: 0001193125-23-277165
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/0001193125-23-277165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/d361794d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277165
- JSON: https://secwatch.observer/filing/0001193125-23-277165.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277165.txt

## Key facts
- Earnings Releases
  Taysha Gene Therapies, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/0001193125-23-277165-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.